- $13.74bn
- $14.42bn
- $1.70bn
- 89
- 13
- 61
- 54
Annual income statement for Insulet, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 738 | 904 | 1,099 | 1,305 | 1,697 |
Cost of Revenue | |||||
Gross Profit | 480 | 582 | 752 | 806 | 1,160 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 697 | 853 | 1,015 | 1,268 | 1,477 |
Operating Profit | 41.3 | 51.5 | 83.6 | 37.6 | 220 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 14.5 | 9.7 | 20.5 | 9.8 | 215 |
Provision for Income Taxes | |||||
Net Income After Taxes | 11.6 | 6.8 | 16.8 | 4.6 | 206 |
Net Income Before Extraordinary Items | |||||
Net Income | 11.6 | 6.8 | 16.8 | 4.6 | 206 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 11.6 | 6.8 | 16.8 | 4.6 | 217 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.298 | 0.103 | 0.752 | 0.258 | 2.94 |